Retinal Biologics Market revenue totalled at around US$ 22.25 Billion in 2022. The global market is expected to reach US$ 41.92 Billion by 2028, surging at a CAGR of 11.1% over the period of 2022 to 2028.
- Increasing prevalence of diabetic eye diseases and age-related macular degeneration (AMD)
- Significant R&D investments engaged in developing biologics for infectious and non-infectious retinal diseases
- Growing application of specific biologic molecules as a promising drug target
- Development of gene therapy as retinal biologics in the wake of large number of monogenic retinal disorders
Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-8663
Retinal Biologics Distribution in Specialty Clinics and Hospitals Prominent
Manufacturers in the retinal biologics market distribute the products through institutional and retail distribution channels. The FMI study finds that institutional sales will garner higher revenues in the retinal biologics market wherein retinal biologics are distributed in specialty clinics and hospitals. Sales in hospitals accounted for over 35% of the market revenues in 2018.
The study estimates that retail sales of retinal biologics will garner similar revenues as that of hospitals and grow at 11.9% in 2019. Retail distribution occurs through retail pharmacies and mail order pharmacies of which retail pharmacies will register higher revenues as compared to its counterparts in the coming years.
Penetration in North America Higher, APEJ’s Attractiveness to Increase
North America continues to hold leading revenues in the retinal biologics market. According to FMI valuation, North America held over 46% of the global retinal biologics market revenues in 2018. Revenues in North America are expected to grow at 10.4% y-o-y in 2019 on the back of increasing prevalence of retinal disorders, steady growth of the healthcare infrastructure and favorable reimbursement scenario.
Europe garnered nearly one-fourth revenues in the retinal biologics market, wherein a bulk of demand penetration was observed in Western European countries such as Germany, the UK, France, Italy, Spain and others. The attractiveness of the APEJ retinal biologics market is expected to rise at the rate of 11% in 2019, wherein China and India remain the most lucrative markets.
Feel free to ask your queries@ https://www.futuremarketinsights.com/ask-question/rep-gb-8663
Retinal Biologics Find Prominent Use in Macular Degeneration Treatment
The study opines that over 35% of the retinal biologics revenues were consolidated in the treatment of macular degeneration. Highest revenue growth of 12.3% is also expected in macular degeneration as compared to other indications where retinal biologics are used in 2019.
Macular degeneration (MD) remains the leading cause of vision loss wherein it affects over 10 million Americans, the prevalence is higher than the combined incidences of cataract and glaucoma, as per the American Macular Degeneration Foundation (AMDF). As macular degeneration mainly affect people of age 50 years or more, with the ageing population, the prevalence of MD continues to rise despite improved treatment options.
Key Players Covered In The Retinal Biologics Market:
- Spark Therapeutics, Inc.
- F. Hoffmann-La Roche Ltd.
- Regeneron Pharmaceuticals, Inc.
- AbbVie Inc.
- Amgen Inc.
- Novartis Pharma AG
- MeiraGTx Limited
- Oxurion NV
- Santen Pharmaceutical Co., Ltd.
- Bayer AG
- Bausch Health Companies Inc.
- Merck & Co., Inc.
Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/8663
Key Segments of Retinal Biologics Industry Survey
Retinal Biologics Market by Drug Class:
- VEGF-A Antagonists
- TNF-α Inhibitors
Retinal Biologics Market by Indication:
- Macular Degeneration
- Diabetic Macular Edema
- Diabetic Retinopathy
- Uveitis
- Others
Retinal Biologics Market by Distribution Channel:
- Institutional Sales
- Retail Pharmacies
- Mail Order Pharmacies
- Retail Sales
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs